Keyword: Aspen Pharmacare
Russia is pushing back on an issue that has raised concerns around the world: cancer drug prices.
European antitrust regulators are looking into Aspen Pharmacare's price hikes on a handful of cancer meds.
Over 7 years, GlaxoSmithKline’s investment in Aspen Pharmacare grew in value sixfold. But that run has come to an end, as GSK wrapped up its final stake sale in the South African company Thursday, raising about $620 million.
AstraZeneca is once again trading off old meds for new money. The U.K.-based pharma off-loaded an anesthetics portfolio to Aspen Pharmacare for up to $770 million, the latest in a string of cash-generating deals.